Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes

OBJECTIVE: To develop a risk assessment tool to identify patients with type 2 diabetes (T2D) at higher risk for kidney disease progression and who might benefit more from sodium–glucose cotransporter 2 (SGLT2) inhibition. RESEARCH DESIGN AND METHODS: A total of 41,204 patients with T2D from four Thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Moura, Filipe A., Berg, David D., Bellavia, Andrea, Dwyer, Jamie P., Mosenzon, Ofri, Scirica, Benjamin M., Wiviott, Stephen D., Bhatt, Deepak L., Raz, Itamar, Feinberg, Mark W., Braunwald, Eugene, Morrow, David A., Sabatine, Marc S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516252/
https://www.ncbi.nlm.nih.gov/pubmed/37556796
http://dx.doi.org/10.2337/dc23-0492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516252/
https://www.ncbi.nlm.nih.gov/pubmed/37556796
http://dx.doi.org/10.2337/dc23-0492

Ejemplares similares